- Home
- KUKE vs AGEN Comparison
KUKE vs AGEN Comparison
Compare KUKE & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- AGEN
- Stock Information
- Founded
- KUKE 2002
- AGEN 1994
- Country
- KUKE China
- AGEN United States
- Employees
- KUKE N/A
- AGEN N/A
- Industry
- KUKE Other Consumer Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KUKE Real Estate
- AGEN Health Care
- Exchange
- KUKE Nasdaq
- AGEN Nasdaq
- Market Cap
- KUKE 86.8M
- AGEN 87.7M
- IPO Year
- KUKE 2021
- AGEN 2000
- Fundamental
- Price
- KUKE $3.07
- AGEN $4.88
- Analyst Decision
- KUKE
- AGEN Buy
- Analyst Count
- KUKE 0
- AGEN 4
- Target Price
- KUKE N/A
- AGEN $13.00
- AVG Volume (30 Days)
- KUKE 8.9K
- AGEN 1.7M
- Earning Date
- KUKE 07-31-2025
- AGEN 08-07-2025
- Dividend Yield
- KUKE N/A
- AGEN N/A
- EPS Growth
- KUKE N/A
- AGEN N/A
- EPS
- KUKE N/A
- AGEN N/A
- Revenue
- KUKE $9,442,397.00
- AGEN $99,524,000.00
- Revenue This Year
- KUKE N/A
- AGEN $12.69
- Revenue Next Year
- KUKE N/A
- AGEN N/A
- P/E Ratio
- KUKE N/A
- AGEN N/A
- Revenue Growth
- KUKE N/A
- AGEN N/A
- 52 Week Low
- KUKE $1.45
- AGEN $1.38
- 52 Week High
- KUKE $17.50
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- KUKE 44.72
- AGEN 55.11
- Support Level
- KUKE $2.95
- AGEN $4.34
- Resistance Level
- KUKE $3.03
- AGEN $5.05
- Average True Range (ATR)
- KUKE 0.11
- AGEN 0.38
- MACD
- KUKE 0.04
- AGEN -0.09
- Stochastic Oscillator
- KUKE 53.54
- AGEN 60.80
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).